FibroBiologics
FBLG
17 hedge funds and large institutions have $5.18M invested in FibroBiologics in 2024 Q1 according to their latest regulatory filings, with 17 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
1.47% more ownership
Funds ownership: 0% → 1.47% (+1.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$2.52M |
| 2 |
HF
HRT Financial
New York
|
+$689K |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$625K |
| 4 |
Citigroup
New York
|
+$366K |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
+$308K |
Top Sellers
FBLG Hedge Fund Activity: Q1 2024 in Review
17 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in FibroBiologics (FBLG) for Q1 2024, worth a combined $5.18M.
Buyers outnumbered sellers: 17 funds opened new FBLG positions and 0 closed out — a net gain of 17 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $2.52M.
- 17 institutional investors held FibroBiologics (FBLG) as of Q1 2024, up from 0 in Q4 2023.
- Funds reported $5.18M of FibroBiologics stock for Q1 2024.
- 17 funds opened new FibroBiologics positions in Q1 2024 and 0 closed out, a net change of +17 holders.
- The largest FibroBiologics buyer in Q1 2024 was Millennium Management, an estimated $2.52M added.
Based on aggregated 13F filings for Q1 2024.